Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Urinary Bladder Neoplasms × Dutasteride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Lower Urinary Tract Symptoms 1 Erectile Dysfunction 1 Adenocarcinoma of the Prostate 1

Interventions

Gemcitabine 82 Cisplatin 58 pembrolizumab 27 Paclitaxel 21 Nivolumab 21 Cystectomy 20 Carboplatin 20 Docetaxel 18 durvalumab 17 atezolizumab 17 Magnetic Resonance Spectroscopy 16 Specimen Handling 15 Radiotherapy 14 Mitomycin 13 avelumab 12 Sunitinib 12 Doxorubicin 12 Methotrexate 11 Fluorouracil 11 Vinblastine 10 Filgrastim 7 BCG Vaccine 7 Sorafenib 6 Ipilimumab 6 Immunoglobulin G 6 Disulfides 6 Biopsy 6 enfortumab vedotin 5 cabozantinib 5 Trastuzumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡